EVAX · Evaxion A/S · Metrics
Market Cap
$33.47M
Shares
9.02M
Volume · Oct 21
326.11K
Avg daily vol (3M)
221.76K
EVAX metrics
59 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$3.71
Market cap
$33.47M
Price action
20 metricsPrice change (1W)
+32.5%
Price change (30D)
+13.5%
Price change (3M)
+22.0%
Price change (6M)
-13.1%
Price change (YTD)
-22.2%
Price change (1Y)
-43.2%
Trailing year
Price change (5Y)
—
52-week high
$6.63
52-week low
$2.76
Change from 52-week high
-44.0%
Change from 52-week low
+34.4%
Annualized volatility
80.7%
Annualized volatility (3M)
71.2%
Beta
0.6
RSI (14D)
63.2
Price vs SMA 50
+16.8%
Price vs SMA 200
+4.0%
Avg volume (3M)
221,756
Relative volume
1.5
Average dollar volume
$717,244
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
9.02M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.5×
reciprocal yield 22.4%
P / book
3.5
reciprocal yield 28.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-20
Profitability
9 metricsGross margin
—
Operating margin
-116.0%
Trailing 12 months
Net margin
-115.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$8.69M
Net income (TTM)
−$8.65M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.49M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2,873.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-90.8%
Return on assets
-44.7%
Debt / equity
—
Current ratio
5.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
5.1
Interest coverage
-3.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$14.00M
Total assets
$19.38M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$7.16M
Capital expenditures (TTM)
$772,000
R&D (TTM)
$10.29M
SG&A (TTM)
—
Stock compensation (TTM)
$413,000
R&D / revenue
137.3%
Stock compensation / revenue
5.5%
Ownership (13F)
9 metrics13F filers
19
13F filer change QoQ
+2
Institutional ownership
17.6%
Conviction holders (share of 13F filers)
5.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.2%
Holder tenure
6.2
Price vs estimated holder cost
-25.2%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
0.6%
Latest settlement · 1.2 days to cover
Days to cover
1.2d
Short-squeeze score
57 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—